Company intelligence
Helus Pharma
Helping Minds Heal
Biotechnology Research
Toronto, CA
105 employees
Founded 2019
3 public signals
About Helus Pharma
At Helus Pharma, we are improving the treatment landscape for mental health. Through our work in small-molecule Novel Serotonergic Agonists (NSAs), we’re advancing patient-centered innovation through clinical excellence aimed at delivering meaningful, durable outcomes that help minds heal.
Verified activity
Signals from Helus Pharma
3 published signals
Presence & Recognition
Helus Pharma CEO Michael Halstead will participate in a fireside chat at the Cantor Global Healthcare Conference taking place September 9-11, 2026 in New York City.
Reported by Helus Pharma
Research & Knowledge
Helus Pharma Senior Vice President and Head of Medical Affairs Ken Kramer, PhD spoke about the Phase 2 program evaluating HLP003 as an adjunctive treatment for major depressive disorder in an interview with Psychiatric Times.
Reported by Helus Pharma
Presence & Recognition
Helus Pharma participated in the Spotlights with RNA Back in the Spotlight event.
Reported by Robert Mino